Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Stargardt disease type 1

Economic burden and healthcare resource utilization

2 evidence topics · 4 sources

Direct healthcare costs: U.S. outpatient claims

“Outpatient administrative claims data (2010–2014)” (opens the source at this quote in a new tab)
“The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71)” (opens the source at this quote in a new tab)

Cost-of-illness studies of inherited retinal diseases: systematic review

“Cost-of-illness studies of inherited retinal diseases: a systematic review” (opens the source at this quote in a new tab)
“non-health costs constituted the overwhelming majority of costs (87 to 98%)” (opens the source at this quote in a new tab)